Vertex Pharmaceuticals Incorporated
VRTX · Price history
Price at last available close
$529.69
+$2.02 (+0.38%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Vertex Pharmaceuticals Incorporated
Primary reporting period: 2025-12-31 · Research updated Oct 5, 2026. A research update is not a new financial filing.
Who they are
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation.
How they make money
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, manufactures, and commercializes transformative medicines for people with serious diseases. The company generates revenue primarily through the sale of its specialty pharmaceutical products to a limited number of specialty pharmacies, specialty distributors, and major wholesalers globally.
Products & services
Vertex develops and markets medicines for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and acute pain, including brands such as TRIKAFTA/KAFTRIO, CASGEVY, ALYFTREK, and JOURNAVX.
Brands & revenue mix
Primary cystic fibrosis therapy driving revenue growth.
Separate brand revenue is not available in this research.
Gene therapy product for sickle cell disease and transfusion-dependent beta thalassemia.
Separate brand revenue is not available in this research.
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Specialty pharmacies
- Specialty distributors
- Major wholesalers
- Hospitals and clinics
Customer concentration
The company sells its medicines primarily to a limited number of specialty pharmacy and specialty distributors globally, as well as to certain major wholesalers in the U.S. as of December 31, 2025.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Strengths
- Leadership in cystic fibrosis treatment
- Robust clinical pipeline in diverse therapeutic areasSource
Risks
- Supply chain disruption or manufacturing capability limitations
- Reliance on third-party contract manufacturers
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
42
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
72
Strong
Financial Strength
65
Business Quality / Moat
72
Management
100
Growth Quality
47
Risk / Durability
72
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
46
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
53/100
Building Historical Record
Model Score 53/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for VRTX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can VRTX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is VRTX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is VRTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What future growth or profitability would be needed to justify VRTX's current valuation?
Essential Investment Snapshot
Wall Street Score
42
Opportunity Score
46
Market Cap
$134.26B
P/E Ratio
29.7
EPS
$17.32
52-Week High
$560.25
52-Week Low
$403.16
Beta
0.32
Intrinsic Value
$513.59
Analyst Target
$601.50
Shares Outstanding
258.0M
Total Revenue
$12.62B
Total Debt
$1.98B
Dividend
No current dividend
Liquidation Value / Share
$78.48
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for VRTX
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on VRTX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Leadership in cystic fibrosis treatment.
- +Robust clinical pipeline in diverse therapeutic areas.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Supply chain disruption or manufacturing capability limitations.
- −Reliance on third-party contract manufacturers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
43
Oct 1, 2026
Change
-0.3
points
Current Score
42
Oct 26, 2026
Category Changes
VRTX decreased 0.3 points because some fundamentals weakened.
Projected Score
Projected Score
44
Projected Change
+2.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Near Fair ValueCurrent Price
$529.69
Model Intrinsic Value
$513.59
Difference
+$16.10
+3.1% vs IV
Margin of Safety
-3.1%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.62B | $12.07B | $11.02B | $9.87B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.76B | $1.81B | $1.53B | $1.26B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $10.86B | $10.27B | $9.49B | $8.61B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $3.96B | $3.75B | $3.63B | $3.16B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $2.01B | $1.75B | $1.46B | $1.14B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $5.99B | $5.51B | $9.72B | $4.78B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $5.50B | $4.87B | $486.3M | $4.61B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $4.87B | $4.76B | -$232.9M | $3.83B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $6.6M | $13.3M | $30.6M | $44.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $5.27B | $4.64B | $248.5M | $4.38B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $869.3M | $690.0M | $784.1M | $760.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $4.41B | $3.95B | -$535.6M | $3.62B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $17.32 | $15.46 | $-2.08 | $14.05 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 254M | 256M | 258M | 258M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 256M | 258M | 258M | 261M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$3.33B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$4.31
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+29.5%
Cash Change
+23.6%
Margin Change
-1.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels. Pressure indicators included debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 12.5%. EPS increased 8.0%. Cash increased 23.6%. Total debt increased 29.5%. Net income margin declined by 1.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
33
Smart Money
33
Number of Gurus
3
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
The $500 Million Non-CF Factor Vertex Investors Can't Ignore on Nov. 2
Rumor Mill · VRTX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial